newsfilter
← Earnings
Earnings Releases·

ADC Therapeutics — Q4 2026 Earnings Summary

  • Clinical data from LOTIS-7 and LOTIS-5 trials demonstrate high efficacy for ZYNLONTA combinations and monotherapy, including an 88.7% overall response rate in LOTIS-7 and a statistically significant progression-free survival benefit in LOTIS-5, though LOTIS-5 showed a higher rate of Grade 5 treatment-emergent adverse events (13.2% vs 4.6%).
  • Management anticipates revenue growth in 2027 and projects a cash runway extending into 2029, while actively pursuing full regulatory approval for ZYNLONTA in earlier lines of therapy and evaluating a potential redomiciliation from Switzerland to Delaware.
  • The company faces significant debt obligations to HealthCare Royalty Management, Blue Owl, and Oaktree, alongside regulatory risks regarding the adequacy of LOTIS-5 data for full approval and ongoing FDA discussions concerning safety concerns raised during the pre-sBLA submission.
  • Strategic initiatives include a filed marketing authorization application for ZYNLONTA in Japan, planned Phase 3 studies for ZYNLONTA plus glofitamab, and upcoming data presentations at the ASH Annual Meeting in December 2026.
Company
ADC THERAPEUTICS SA
Sector
Healthcare
Industry
Biotechnology